Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF)

Yasmine S. Ali, MD

Disclosures

June 10, 2021

A beta-blocker should be part of the therapeutic regimen for any patient with symptomatic HFrEF. Diuretics should be used on an as-needed basis to relieve the signs and symptoms of congestion.

In conjunction with an evidence-based beta-blocker, the ACC recommends that patients with symptomatic HFrEF receive an angiotensin-converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB), or an angiotensin receptor-neprilysin inhibitor (ARNI). The role of ARNI in guideline-directed medical therapy for HF has increased, and treatment with an ARNI may now be initiated without first starting an ACEI or ARB.

They also recommend the use of an l f current inhibitor to reduce HF hospitalization for patients with symptomatic, stable, chronic HFrEF who are receiving guideline-directed evaluation and management, including the maximum tolerated dose of beta-blocker, and who are in sinus rhythm, with a heart rate ≥ 70 beats/min at rest.

The treatment algorithm recommended by the ESC for patients with symptomatic HFrEF starts with dual treatment using an ACEI and a beta-blocker.

Mineralocorticosteroid receptors should be added for patients who are still symptomatic despite baseline therapy and whose LVEF is ≤ 35%. If patients are still symptomatic with reduced LVEF, an ARNI may replace the ACEI for patients able to tolerate an ACEI. Patients in sinus rhythm with a heart rate ≥ 70 beats/min can be treated with an l f current inhibitor.

Learn more about guideline-directed pharmacotherapy in HFrEF.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....